MedTrace Logo

Pazopanib for Treating Uterine Leiomyosarcoma

NCT02378142 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-11-18

No results posted yet for this study

Summary

The purpose of this study is to test any good and bad effects of the study drug pazopanib.

Conditions

  • Uterine Leiomyosarcoma

Interventions

DRUG

Pazopanib

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • Martee Hensley, MD · MSKCC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-01-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02378142 on ClinicalTrials.gov